Evidence map›Paper›PMID 37082104›Full record

ArticleJournal of biomedical optics2023

Dual probe difference specimen imaging for prostate cancer margin assessment.

Marcus J Kwon, Broderick J House, Connor W Barth, Allison Solanki, Jocelyn A Jones, Scott C Davis, Summer L Gibbs

Open access · goldAbstract read
In one paragraph

Article in Journal of biomedical optics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marcus J KwonOregon Health & Science University, Biomedical Engineering Department, Portland, Oregon, United States.ORCID 0000-0001-6083-5761
Broderick J HouseOregon Health & Science University, Biomedical Engineering Department, Portland, Oregon, United States.
Connor W BarthOregon Health & Science University, Biomedical Engineering Department, Portland, Oregon, United States.ORCID 0000-0002-6235-7238
Allison SolankiOregon Health & Science University, Biomedical Engineering Department, Portland, Oregon, United States.
Jocelyn A JonesOregon Health & Science University, Biomedical Engineering Department, Portland, Oregon, United States.ORCID 0000-0002-3836-6433
Scott C DavisThayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States.
Summer L GibbsOregon Health & Science University, Biomedical Engineering Department, Portland, Oregon, United States.ORCID 0000-0001-8077-1582
Oregon Health & Science University · USDartmouth College · US

Funding

Multi-probe fluorescence imaging for rapid intra-operative tumor margin assessmentR01CA188491 · NCI · DARTMOUTH COLLEGE · PI DAVIS, SCOTT C · 2015 to 2019
$2.9M
NCI NIH HHS R01 CA188491
6 · The paper itself

Abstract

Significance: Positive margin status due to incomplete removal of tumor tissue during radical prostatectomy for high-risk localized prostate cancer requires reoperation or adjuvant therapy, which increases morbidity and mortality. Adverse effects of prostate cancer treatments commonly include erectile dysfunction, urinary incontinence, and bowel dysfunction, making successful initial curative prostatectomy imperative. Aim: Current intraoperative tumor margin assessment is largely limited to frozen section analysis, which is a lengthy, labor-intensive process that is obtrusive to the clinical workflow within the operating room (OR). Therefore, a rapid method for prostate cancer margin assessment in the OR could improve outcomes for patients. Approach: Dual probe difference specimen imaging (DDSI), which uses paired antibody-based probes that are labeled with spectrally distinct fluorophores, was shown herein for prostate cancer margin assessment. The paired antibody-based probes consisted of a targeted probe to prostate-specific membrane antigen (PSMA) and an untargeted probe, which were used as a cocktail to stain resected murine tissue specimens including prostate tumor, adipose, muscle, and normal prostate. Ratiometric images (i.e., DDSI) of the difference between targeted and untargeted probe uptake were calculated and evaluated for accuracy using receiver operator characteristic curve analysis with area under the curve values used to evaluate the utility of the DDSI method to detect PSMA positive prostate cancer. Results: Targeted and untargeted probe uptake was similar between the high and low PSMA expressing tumor due to nonspecific probe uptake after topical administration. The ratiometric DDSI approach showed substantial contrast difference between the PSMA positive tumors and their respective normal tissues (prostate, adipose, muscle). Furthermore, DDSI showed substantial contrast difference between the high PSMA expressing tumors and the minimally PSMA expressing tumors due to the ratiometric correction for the nonspecific uptake patterns in resected tissues. Conclusions: Previous work has shown that ratiometic imaging has strong predictive value for breast cancer margin status using topical administration. Translation of the ratiometric DDSI methodology herein from breast to prostate cancers demonstrates it as a robust, ratiometric technique that provides a molecularly specific imaging modality for intraoperative margin detection. Using the validated DDSI protocol on resected prostate cancers permitted rapid and accurate assessment of PSMA status as a surrogate for prostate cancer margin status. Future studies will further evaluate the utility of this technology to quantitatively characterize prostate margin status using PSMA as a biomarker.

Indexed as

Prostatic NeoplasmsDiagnostic ImagingHumansMaleProstateProstatectomydual probe difference specimen imagingfluorescence guided surgeryprostate cancerprostatectomytumor margin assessment

Identifiers

PMID37082104
PMCPMC10111791
OpenAlexW4366284229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.